|
Valuing
Healthcare Innovation
EuropaBio
would like to see a
greater move towards
patient-centered
healthcare systems in
Europe, and a change
from ‘protecting’ to
‘promoting’ public
health - so as to bring
more innovation to
patients. In order to
achieve this, Members
States need to implement
balanced, pro-innovation
public health policies
that do not misuse
public
health technology
assessments.
However, biotech
medicines must undergo a
number of potential
stumbling blocks before
reaching the patients:
-
Policy-makers face
tremendous
challenges when
making
recommendations for
the adoption of new
therapies.
-
The
perceived value of a
therapy may differ
depending on whether
one is a payer, a
patient, a family
member, or a
physician involved
in the healthcare of
a patient.
-
Pricing and
reimbursement
procedures set by Member
States
continue to show
difficulties in
encompassing and
capturing the value,
and subsequent
rewarding, of the
use of biotech in
bringing and
delivering
innovative treatment
to patients.
-
The
fullest possible
transparency and
stakeholder
involvement are
basic and necessary
components that are
often lacking when
healthcare
allocation decisions
are judgmental and
value-driven.
EuropaBio
wants to see the
building a policy agenda
to:
-
Ensure an
appropriate system
to reward innovation
-
Maintain an
industrial climate
that is favorable
for innovation
-
Ensure strong and
coherent political
support and
leadership to
realize long-term
investments in
healthcare
To
support this campaign,
EuropaBio's Healthcare
Council has organised a taskforce on
the
Value of Innovation.
Chairman: Mr. John
LEPORE (GlaxoSmithKline)
Secretary: Mr. Michael
LEADER (EuropaBio)
Articles
Testing New Technology
- Article by Healthcare
Council Chair Andrea
Rappagliosi in the
Public Service Review:
European Union
Health
Technology Assessments
To date, there continues
to be no commonly shared
European consensus on
how to reward healthcare
innovation. Health
Technology Assessment (HTA)
- is often used as the
mechanism by which
governments decide the
value of new therapies.
Different mechanisms to
evaluate such clinical
and/or
cost-effectiveness are
used in a majority of
European Union member
states, at all times
separate from regulatory
product registrations.
Unfortunately, in a
variety of healthcare
systems
cost-effectiveness or
cost-utility models with
a limited systematic
review of clinical data
are presented as HTA and
"pretend" to have the
statute of a holistic
evaluation of
technologies when they
are not .Such HTA
evaluations can have the
impact of punishing
research-intensive
biotech SMEs and also
threatening patient
access by possible
misuse as a tool of
cost-containment/rationing
policies in healthcare.
 back
|
